AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01068119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Same-day discharge
Description: Patients identified as clinically stable are discharged home the same day as the PCI procedure with telephone follow-up at 12 hr, 24 hr, 3, 30, 180 and 365 days post procedure.
Study NCT04679792 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic posturography
Description: Balance evaluation
Study NCT06320730 — intervention group
Intervention type: OTHER
Intervention: Observational study, records of blood glucose level after reperfusion
Description: Analyzes blood glucose level after reperfusion by dividing it into two groups: those with blood glucose levels between 110 and 180 and those with blood glucose levels below 110 or above 180.
Study NCT00229177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2506
Description: Once daily one-hour intravenous infusion at 8 mg/kg/hr for 7 days
Study NCT01105624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin ophthalmic solution, 1%
Description: 1 drop BID for the first 2 days and then 1 drop QD for the remainder of treatment period (29 ± 1 day)
Study NCT01105624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visine® for Contacts®
Description: 1-2 drops QID for the treatment period (29 ± 1 day)
Study NCT00761657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Capsule
Study NCT03028831 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 70g of fully digestible starch amylopectin corn starch
Description: Fully digestible amylopectin corn starch
Study NCT00761657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study NCT02033538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel
Description: Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
Study NCT02302989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5mg
Study NCT02568449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Given PO
Study NCT04213170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 q21d
Study NCT03028831 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resistant starch
Description: 70g high-amylose maize starch
Study NCT00439426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2 iv on day 1 of each 3 week cycle
Study NCT04527523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography
Description: OCT is an imaging method that uses light waves to create images of the retina.
Study NCT00283816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg. tabs 2 tabs BID for duration of study
Study NCT00283816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Contraceptive Pill
Description: Yasmin, drospirenone and ethinyl estradiol 28 tablets~1 tab daily for duration of study
Study NCT00283816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Contraceptive Pill
Description: Yasmin, drospirenone and ethinyl estradiol 28 tablets~1 tab daily for duration of study
Study NCT00283816 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle Management Program
Description: Subjects and a parent/guardian will participate in a series of classes for training in diet, exercise \& behavior modification skills on a regular weekly basis over the 24 week study
Study NCT00283816 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Management Program
Description: Subjects and a parent/guardian will participate in a series of classes for training in diet, exercise \& behavior modification skills on a regular weekly basis over the 24 week study
Study NCT00283816 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Quality of Life Questionnaire
Description: Quality of Life questionnaire designed for women with Polycystic Ovary Syndrome. Questions concern health and health related issues Performed twice during study, at baseline and conclusion
Study NCT00283816 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life Questionnaire
Description: Quality of Life questionnaire designed for women with Polycystic Ovary Syndrome. Questions concern health and health related issues Performed twice during study, at baseline and conclusion
Study NCT00283816 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: Insulin response to a glucose challenge in an oral glucose tolerance test (OGTT), as measured by area under the curve (AUC). In this study we will administer an OGTT and calculate the AUC as a measure of insulin resistance.~Performed twice during study, at baseline and conclusion
Study NCT00283816 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: Insulin response to a glucose challenge in an oral glucose tolerance test (OGTT), as measured by area under the curve (AUC). In this study we will administer an OGTT and calculate the AUC as a measure of insulin resistance.~Performed twice during study, at baseline and conclusion
Study NCT00283816 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood work
Description: Initial and conclusion blood draws include; comprehensive metabolic profile, CBC and platelet,hormonal assessment and lipids.
Study NCT00283816 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood work
Description: Initial and conclusion blood draws include; comprehensive metabolic profile, CBC and platelet,hormonal assessment and lipids.
Study NCT00283816 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Abdominal Ultra Sound
Description: transabdominal transducer, which contains integrated software for volume calculation will be used to assess ovarian volume.~Performed twice during study, at baseline and conclusion
Study NCT00283816 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Ultra Sound
Description: transabdominal transducer, which contains integrated software for volume calculation will be used to assess ovarian volume.~Performed twice during study, at baseline and conclusion
Study NCT00283816 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dual-energy x-ray absorptiometry (DEXA scan)
Description: Dual-energy x-ray absorptiometry (DEXA) will be used to assess percent body fat Performed twice during study, at baseline and conclusion
Study NCT00283816 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dual-energy x-ray absorptiometry (DEXA scan)
Description: Dual-energy x-ray absorptiometry (DEXA) will be used to assess percent body fat Performed twice during study, at baseline and conclusion
Study NCT00283816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules, two capsules BID
Study NCT01584674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KLOX Biophotonic System
Description: KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
Study NCT01444027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Description: Problem-solving therapy (PST) focuses on behavioral change principles derived from this theoretical framework. PST addresses four skills: 1) problem definition and formulation, which involves gathering data and information, articulating the issue in clear terms, identifying the challenge, and setting realistic goals; 2) generation of alternative strategies; 3) decision making; and 4) solution implementation. The intervention is delivered in a series of interactions with the interventionist.
Study NCT04423601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390 tablet
Description: single oral dose of SHR6390 or co-administered with itraconazole.
Study NCT04423601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole capsule
Description: 200 mg itraconazole was administered in the morning.
Study NCT01594749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01594749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Study NCT01594749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Study NCT01594749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Placebo
Study NCT01594749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Placebo
Study NCT03508323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin
Description: 20mg/qd
Study NCT01594749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue Therapy
Study NCT01594749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Therapy
Study NCT03932292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ectoin Mouth Wash
Description: According to medical prescription of the instruction for use under consideration (at least 4x1 ampoule (5ml) daily, rinsed in the mouth for at least 30 seconds)
Study NCT03508323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1T/qd
Study NCT00432744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CoenzymeQ10
Description: CoenzymeQ10 will be given in 10 mg/kg daily up to 400 mg. Then a draw of CoQ10 troughs every three months will be performed.
Study NCT00432744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in 10 mg/kg daily up to 400 mg. Then a draw of placebo troughs every three months will be performed. This treatment group will be treated as the active group.
Study NCT00439426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg/m2 po bid on days 1-14 of each 3 week cycle
Study NCT01080690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EGD
Description: In this arm EGD will be performed before EUS.
Study NCT01080690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS
Description: In this arm EUS will be performed before EGD.
Study NCT03128112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exam room with poster
Description: This intervention will assess whether a novel educational exam room poster can effectively prompt patients to ask pediatricians about their children's weight status and improve patents' perceptions of their children's weight status.
Study NCT03932292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supersaturated solution of calcium and phosphate ions
Description: According to medical prescription of the instruction for use under consideration (4 times a day).
Study NCT03698695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THN 201
Description: THN 201: Donepezil 5 mg and Mefloquine 10 mg/d
Study NCT03698695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil 5 mg/d and Mefloquine placebo
Study NCT03698695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Donepezil placebo and Mefloquine placebo
Study NCT02716532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Peptamen AF
Description: Each patient will receive Peptamen AF throughout the trial.
Study NCT03853057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: body positions
Description: positive pressure ventilation at different body positions
Study NCT02045615 — intervention group
Intervention type: PROCEDURE
Intervention: Proposed technique for removal of the Wichita Fusion Nail
Study NCT03557801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mammography with Community Health Worker (individual)
Description: Immediately following consent and completion of the baseline assessment, alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
Study NCT03557801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mammography with Community Health Worker (group)
Description: Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
Study NCT03198364 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety and Recovery Therapy
Description: 4 session individualized psychoeducation tailored to people with bipolar disorder or schizophrenia targeting coping skills for suicidal thoughts and their determinants.
Study NCT03198364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety and Recovery Therapy
Description: 4 session individualized psychoeducation tailored to people with bipolar disorder or schizophrenia targeting coping skills for suicidal thoughts and their determinants.
Study NCT03557801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Mammography
Description: Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard protocol.
Study NCT02353806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate
Description: Pregnant and postpartum women will continue taking amlodipine besylate 5 mg for treatment of chronic hypertension as prescribed by their clinician.
Study NCT03985566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fibre Grain
Description: Healthy subjects will be provided with 30% Fibre Grain in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
Study NCT03985566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Jasmine white rice
Description: Healthy subjects will be provided with Jasmine white rice in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
Study NCT01486459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: 250 mg daily for 6 weeks, increased 250 - 500 mg depending on plasma levels.
Study NCT00689351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
Study NCT00689351 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine
Description: 7vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
Study NCT01513733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasquinimod
Description: tasquinimod 0.25 mg continuously
Study NCT01513733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasquinimod 0.25 mg; 0.5 mg
Description: tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
Study NCT01513733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
Description: tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
Study NCT01766206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM (Menveo)
Description: One dose administered intramuscularly preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle in children, adolescents and adults.
Study NCT02198313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIX 1 XX - D1
Study NCT02198313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIX 1 XX - D2
Study NCT02631954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorico Injection 200mg(Voriconazole)
Description: Vorico Injection 200mg(Voriconazole) to administered intravenously once
Study NCT02631954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vfend®(Voriconazole) IV 200mg
Description: Vfend®(Voriconazole) IV 200mg to administered intravenously once
Study NCT03905122 — intervention group
Intervention type: DEVICE
Intervention: bioreactans tool
Description: It is a completely non-invasive method by bioreactance method and it can be done to measure the intra-body fluid status with the help of the probes.
Study NCT01670799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: This is a pilot (feasibility) trial to determine the availability, concentration and racemic mixture of a clinically indicated pain medication, ketorolac, in the peritoneal cavity and the subsequent effect on free floating ovarian cancer cells in patients after cytoreductive surgery for ovarian cancer.
Study NCT03198364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Augmentation
Description: Though a smartphone device, participants receive 12 weeks of personalized prompts derived from content produced in individual START sessions to increase transfer of skills to day to day life
Study NCT03622437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-led follow-up
Description: 1. Patient-education, with information about signs of recurrent disease (alarm-symptoms), potential late effects, and how these can be managed.~2. The patients are instructed to contact a specialist nurse in case of alarm-symptoms, concerns or other problems related to the cancer disease throughout the entire follow-up period. The specialist nurse responds to the referrals, according to a standardized algorithm.~In addition, all patients receive:~* CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~* perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years~Only for patients with a stoma:~- access to stoma care by specialist nurses
Study NCT03622437 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Description: Patients with sphincter-preserving resection:~- outpatient visits incl. rectoscopy at 6, 12, 18, 24 and 36 months~Patients with rectal amputation and a permanent stoma:~* outpatient visits at 3, 12 and 36 months~* access to stoma care by specialist nurses~All patients:~* CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~* perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years
Study NCT01564498 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vegetable
Description: 200-300 g raw carrots or 300-500 g cooked potatoes
Study NCT01564498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vegetable
Description: 200-300 g raw carrots or 300-500 g cooked potatoes
Study NCT02553148 — intervention group
Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care
Study NCT01132157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
Study NCT01132157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
Study NCT04019314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: Samples for proEnkephalin PENK will be obtained daily and aliquots of these samples will be stored for later batch assays.
Study NCT04019314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Volume Analysis
Description: A small amount of a radioactive isotope or tracer is injected and blood samples are taken at 6 time points during the test and analyzed.
Study NCT00410553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV
Study NCT00410553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01948232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril
Description: Angiotensin converting enzyme inhibitor
Study NCT00039338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Radial hysterectomy
Study NCT00039338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy
Description: Experimental arm: minimal cumulative cisplatin dose of 225 mg/m2. Comparator arm: cumulative cisplatin dose of 200-240 mg/m2.